For healthcare professionals. This content is intended for practitioners only.
This article provides a clinical reference for the THERA Nordic product range, covering the primary indication and mechanism for each product, and evidence-based combination protocols for common presentations.
Product Selection Guide
REZCUE (Zinc L-Carnosine + L-Glutamine) The core mucosal healing product. Primary indication: gut barrier restoration, active GI inflammation, and mucosal repair following damage from any cause — including NSAIDs, antibiotics, stress, or inflammatory disease. Best suited to: GERD, gastritis, gastric and duodenal ulcer, IBS with a permeability component, IBD (Crohn's and UC), NSAID-induced mucosal damage, and post-antibiotic gut restoration.
Not recommended in: pregnancy, breastfeeding, severe renal or hepatic disease, or seizure disorders.
Bacti-Balance (Multi-strain probiotic) Primary indication: microbiome restoration and immune modulation. Best suited to post-antibiotic dysbiosis, recurrent infections, IBS-D, and traveller's diarrhoea prevention. Can be co-administered with REZCUE — probiotics are not affected by zinc at standard REZCUE doses.
Daily Healthy Fibre (Soluble and insoluble fibre blend) Primary indication: bowel regularity and prebiotic support. Best suited to IBS-C, constipation-dominant presentations, and patients with metabolic syndrome or cardiovascular risk factors where cholesterol management is relevant. Advise adequate hydration and a slow titration in IBS patients to avoid bloating.
Triple HCL (Betaine HCL + Pepsin) Primary indication: hypochlorhydria and protein maldigestion. Best suited to patients with suspected low gastric acid — clinical indicators include belching after meals, undigested food in stool, SIBO history, or low B12 and iron with no other explanation. Also appropriate for patients on long-term PPIs and elderly patients with age-related reduction in gastric acid output.
Important contraindication: Do not use Triple HCL in patients with active gastric or duodenal ulceration, or alongside NSAIDs, without concurrent mucosal protection. In these cases, combine with REZCUE.
Titration protocol: Begin with 1 capsule per main protein-containing meal. Increase by 1 capsule every 3–5 days until a warm or burning sensation is felt, then reduce by 1 capsule. This identifies the patient's optimal dose.
HEALIA (Collagen + joint support) Primary indication: joint health and connective tissue support. For patients where gut absorption is a concern — a common clinical consideration with collagen products — consider REZCUE or Triple HCL to optimise digestive function prior to or concurrent with HEALIA.
Move (Magnesium) Primary indication: muscle function, sleep quality, and nervous system support. The high bioavailability form supports ATP production, muscle relaxation, GABA modulation, and has evidence for migraine prophylaxis. Also useful as a gentle approach to constipation management, as magnesium draws water into the bowel.
Combination Protocols for Common Presentations
Leaky gut / intestinal permeability REZCUE (standard dose) + Bacti-Balance + Daily Healthy Fibre. The rationale: REZCUE addresses mucosal repair at the tight junction level; Bacti-Balance restores commensal bacterial populations disrupted by the same underlying dysfunction; Daily Healthy Fibre provides fermentable substrate for butyrate production, which in turn supports colonocyte health.
Post-PPI weaning REZCUE at standard dose, introduced alongside the current PPI. At week 2, reduce PPI dose by 50%. Target full cessation by weeks 4–6. If symptoms recur, maintain low-dose PPI and continue REZCUE for a further 4 weeks before attempting wean again.
Post-antibiotic gut restoration REZCUE (4-week course, standard dose) + Bacti-Balance concurrent. REZCUE addresses the antibiotic-induced mucosal damage that is frequently overlooked; Bacti-Balance restores the commensal populations disrupted by antibiotic use.
SIBO management Triple HCL (to restore the gastric acid barrier that prevents bacterial overgrowth from recurring) + Daily Healthy Fibre (to support motility). Add REZCUE if mucosal damage is also present. Important: delay introducing probiotics until SIBO is confirmed resolved to avoid adding substrate for bacterial growth.
IBS-D with permeability component REZCUE (mucosal barrier repair) + Bacti-Balance (microbiome stabilisation). Concurrent low FODMAP dietary advice is recommended.
IBD maintenance between flares REZCUE (standard dose) + Bacti-Balance for ongoing support. During flares: escalate REZCUE to intervention dose. If the patient has distal or rectal involvement, rectal REZCUE administration should be considered.
